# Tecemotide (L-BLP25) in Rectal Cancer

> **NCT01507103** · PHASE2 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 124 (actual)

## Conditions studied

- Rectal Cancer

## Interventions

- **BIOLOGICAL:** Tecemotide (L-BLP25)
- **DRUG:** cyclophosphamide (CPA)
- **OTHER:** Chemoradiotherapy

## Key facts

- **NCT ID:** NCT01507103
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2017-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01507103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01507103, "Tecemotide (L-BLP25) in Rectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01507103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*